白细胞介素-37:常染色体显性多囊肾病的新治疗靶点
常染色体显性多囊肾病(ADPKD)虽为遗传性肾脏病,但肾脏免疫微环境在疾病进展和严重程度中起关键作用。Zylberberg等在本期发表的研究显示,白细胞介素-37通过激活肾巨噬细胞中的干扰素信号通路抑制ADPKD起始,提示其作为潜在免疫调节疗法的可能。
要点
- ADPKD进展受肾脏免疫微环境影响
- IL-37激活肾巨噬细胞干扰素信号
- IL-37抑制ADPKD起始,具治疗潜力
核心结论
- 白细胞介素-37通过激活肾巨噬细胞干扰素信号抑制ADPKD起始,是潜在免疫调节治疗靶点。
研究设计与样本
- Zylberberg等在当期发表的研究,具体设计与样本量原文未报告。
主要发现
- 白细胞介素-37激活肾巨噬细胞中的干扰素信号通路。
- 该信号激活抑制ADPKD的起始。
临床怎么用
- 提示白细胞介素-37可作为ADPKD的潜在免疫调节疗法方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) has long been considered a genetic renal disorder, but emerging evidence suggests that the immune microenvironment within the kidney plays a pivotal role in disease progression and severity. In recent years, the previously obscure cytokine interleukin-37 has proved a strong inhibitor of innate immunity in multiple disease models. However, its role in ADPKD has not received scrutiny. In a provocative study published in the current issue, Zylberberg et al. show that interleukin-37 activates interferon signaling in renal macrophages, which inhibits ADPKD initiation. This finding identifies interleukin-37 as a potential viable immunomodulatory therapy for ADPKD.
引用
- Yang B, Crowley SD. Interleukin-37: a new therapeutic target in autosomal dominant polycystic kidney disease. Kidney Int. 2024. PMID: 38519230. doi:10.1016/j.kint.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。